Advertisement

Colorectal Cancer

  • H. L. Kindler
  • R. L. Schilsky
Chapter

Abstract

Colorectal cancer is a major public health problem in Western countries with the highest incidence rates reported in North America, Australia, New Zealand, and western Europe. An estimated 135,000 cases will be diagnosed in the United States in 2001 and approximately 57,000 people will die of the disease [1]. Colorectal cancer is the third most common cancer in men and women and the third most common cause of cancer death in both sexes. The age-specific incidence rises sharply after age 40, with 90 % of cancers occurring in individuals age 50 and older. Within the large intestine, 69 % of cancers occur in the colon and 31% in the rectum. More than half of all colonic cancers occur either in the sigmoid colon (35 %) or in the cecum (22 %), although, in recent years, right-sided lesions are becoming more common [2].

Keywords

Colorectal Cancer Rectal Cancer Clin Oncol Familial Adenomatous Polyposis Lynch Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenlee RT, Hill-Harmon MB, Murray, T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15–36PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen AM, Minsky BD, Schilsky RL (1997) Cancer of the colon. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. LippincottRaven, Philadelphia, pp 1144–1197Google Scholar
  3. 3.
    Rustgi AK (1994) Hereditary gastrointestinal polyposis and non-polyposis syndromes. N Engl J Med 331:1694–1702PubMedCrossRefGoogle Scholar
  4. 4.
    Lynch HT, Smyrk T (1996) Hereditary non-polyposis colorectal cancer (Lynch Syndrome). Cancer 78:1149–1167PubMedCrossRefGoogle Scholar
  5. 5.
    Rhyu MS (1996) Molecular mechanisms underlying hereditary non-polyposis colorectal carcinoma. J Natl Cancer Inst 88:240–251PubMedCrossRefGoogle Scholar
  6. 6.
    Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Science 61:759–767Google Scholar
  7. 7.
    Kinzler KW, Nilbert MC, Vogelstein B et al (1991) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251:1366–1369PubMedCrossRefGoogle Scholar
  8. 8.
    Baker SJ, Fearon ER, Nigro JM et al (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221PubMedCrossRefGoogle Scholar
  9. 9.
    Fearon ER, Cho KR, Nigro JM et al (1990) Identification of a chromosome 18q gene that is altered in colorectal cancer. Science 247:49–56PubMedCrossRefGoogle Scholar
  10. 10.
    Riddell RH (1995) Inflammatory bowel disease and colorectal cancer. In: Cohen AM, Winawer SJ, Friedman MA, Gunderson LL (eds) Cancer of the colon, rectum and anus. McGraw-Hill, New York, pp 105–119Google Scholar
  11. 11.
    Winawer SJ, Shike M (1992) Dietary factors in colorectal cancer and their possible effects in earlier stages on hyperproliferation and adenoma formation. J Natl Cancer Inst 84:74–75PubMedCrossRefGoogle Scholar
  12. 12.
    Giovannucci E, Stampfer MJ, Colditz G et al (1992) Relationship of diet to risk of colorectal adenoma in men. J Natl Cancer Inst 84:91–98PubMedCrossRefGoogle Scholar
  13. 13.
    Martinez ME, Giovannucci EL, Colditz GA et al (1996) Calcium, vitamin D and the occurrence of colorectal cancer among women. J Natl Cancer Inst 88:1375–1382PubMedCrossRefGoogle Scholar
  14. 14.
    MacLennan R, Macrae F, Bain C et al (1995) Randomized trial of intake of fat, fiber and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst 87:1760–1766PubMedCrossRefGoogle Scholar
  15. 15.
    Alberts DS, Martinez ME, Roe DJ et al (2000) Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N Engl J Med 342:1156–1162PubMedCrossRefGoogle Scholar
  16. 16.
    Minsky BD, Mies C, Rich TA et al (1989) Lymphatic vessel invasion is an independent prognostic factor for survival in colorectal cancer. Int J Radiat Oncol 17:311–318CrossRefGoogle Scholar
  17. 17.
    Knudsen JB, Nilsson T, Sprechler M et al (1983) Venous and nerve invasion as prognostic factors in postoperative survival of patients with resectable cancer of the rectum. Dis Colon Rectum 26:613–617PubMedCrossRefGoogle Scholar
  18. 18.
    Witzig TE, Loprinzi CL, Gonchoroff NJ et al (1991) DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 an C colorectal adenocarcinoma. Cancer 68:879–888PubMedCrossRefGoogle Scholar
  19. 19.
    Shibata D, Reale MA, Lavin P et al (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335: 1727–1732PubMedCrossRefGoogle Scholar
  20. 20.
    Lenz H-J, Danenberg KD, Danenberg P et al (1996) p53 status and thymidylate synthase expression are associated and predict for recurrence in patients with stage II colon cancer (abstract). Proc Am Soc Clin Oncol 15:215Google Scholar
  21. 21.
    Ahnen DJ, Feigl P, Quan G et al (1998) Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58:1149–1158PubMedGoogle Scholar
  22. 22.
    Watanabe T, Wu T-T, Catalano PJ et al (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196–1206PubMedCrossRefGoogle Scholar
  23. 23.
    Ogunbiyi OA, Goodfellow PJ, Herfarth K et al (1998) Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16:427–433PubMedGoogle Scholar
  24. 24.
    Patt YZ, Hogue A, Podoloff DA et al (1996) CEA-Scan, a 99Tclabeled Fab fragment of moAb anti-CEA immu-4 for radioimmunodetection of occult metastatic colorectal cancer in patients with rising serum CEA: a multi-institutional study (abstract). Proc Am Soc Clin Oncol 15:208Google Scholar
  25. 25.
    Tempero M, Brand R, Holdeman K, Matamoros A (1995) New imaging techniques in colorectal cancer. Semin Oncol 22:448–471PubMedGoogle Scholar
  26. 26.
    Moertel CG, Fleming TR, MacDonald JS et al (1995) 5-FU plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMedGoogle Scholar
  27. 27.
    Wolmark N, Rockette H, Fisher B et al (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 11:1879–1887PubMedGoogle Scholar
  28. 28.
    International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939–944CrossRefGoogle Scholar
  29. 29.
    Zaniboni A (1997) Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 15:2432–2441PubMedGoogle Scholar
  30. 30.
    O’C onnell MJ, Mailliard JA, Kahn MJ et al (1997) A controlled trial of 5-fiuorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246–250PubMedGoogle Scholar
  31. 31.
    Haller DG, Catalano DJ, MacDonald JS et al (1998) Fluorouracil (FU), leucovorin (LV) and levamisole (lev) adjuvant therapy for colon cancer: five-year final report of INT-0089 (abstract). Proc Am Soc Clin Oncol 17:982AGoogle Scholar
  32. 32.
    Wolmark N, Rockette H, Mamounas EP et al (1996) The relative efficacy of 5-FU + leucovorin (FU-LU), 5-FU and levamisole (FU-Lev), and 5-FU + leucovorin and levamisole (FU-LV-lev) in patients with Dukes’ B and C carcinoma of the colon: first report of NSABP C-04 (abstract). Proc Am Soc Clin Oncol 15:205Google Scholar
  33. 33.
    O’Connell MJ, Laurie JA, Kahn M et al (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high risk colon cancer. J Clin Oncol 16:295–300PubMedGoogle Scholar
  34. 34.
    Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, C-04). J Clin Oncol 17:1349–1355PubMedGoogle Scholar
  35. 35.
    International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356–1363Google Scholar
  36. 36.
    Riethmuller G, Schneider-Gadicke E, Schlimok G et al (1994) Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 343:1177–1183PubMedCrossRefGoogle Scholar
  37. 37.
    Punt CJ, Nagy A, Douillard J et al (2001) Edrecolomab (17-1A antibody) alone or in combination with 5-fiuorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study (abstract). Proc Am Soc Clin Oncol 20:123AGoogle Scholar
  38. 38.
    Wolmark N, Rockette H, Petrelli N et al (1994) Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer: NSABP C-02 (abstract). Proc Am Soc Clin Oncol 13:194Google Scholar
  39. 39.
    Liver Infusion Meta-analysis Group (1997) Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 89:497–505CrossRefGoogle Scholar
  40. 40.
    Freedman GM, Coia LR (1995) Adjuvant and neoadjuvant treatment of rectal cancer. Semin Oncol 22:611–624PubMedGoogle Scholar
  41. 41.
    Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987CrossRefGoogle Scholar
  42. 42.
    Gastrointestinal Tumor Study Group (1985) Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 312:1465–1472CrossRefGoogle Scholar
  43. 43.
    Gastrointestinal Tumor Study Group (1986) Survival after postoperative combination treatment of rectal carcinoma. N Engl J Med 315:1294–1295CrossRefGoogle Scholar
  44. 44.
    Krook JE, Moertel CG, Gunderson LL et al (1991) Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709–715PubMedCrossRefGoogle Scholar
  45. 45.
    O’Connell MJ, Martenson JA, Wieand HS et al (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion 5-FU with radiation therapy after curative surgery. N Engl J Med 331:502–507PubMedCrossRefGoogle Scholar
  46. 46.
    Tepper J, O’Connell M, Petroni G et al (1996) Toxicity in the adjuvant therapy of rectal cancer: a preliminary report of intergroup O114 (abstract). Proc Am Soc Clin Oncol 15:210Google Scholar
  47. 47.
    Steele GD, Herndon JE, Bleday R et al (1999) Sphincter sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol 6:433–441PubMedCrossRefGoogle Scholar
  48. 48.
    Cromheecke M, de Jong KP, Hoekstra HJ (1999) Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol 25:451–463PubMedCrossRefGoogle Scholar
  49. 49.
    Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946PubMedGoogle Scholar
  50. 50.
    McCormack PM, Burt ME, Bains MNS et al (1992) Lung resection for colorectal metastases: 10 year results. Arch Surg 127:1403–1406PubMedCrossRefGoogle Scholar
  51. 51.
    Keyomarsi K, Moran RG (1986) Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 46:5229–5235PubMedGoogle Scholar
  52. 52.
    Advanced Colorectal Cancer Meta-Analysis Project (ACCNAP) (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10:896–903Google Scholar
  53. 53.
    Sotos GA, Allegra CJ (1996) Biochemical modulation of cancer chemotherapy. In: Schilsky RL, Milano GA, Ratain MJ (eds) Principles of antineoplastic drug development and pharmacology. Dekker, New York, pp 143–187Google Scholar
  54. 54.
    Blanke CD, Kasimis B, Schein P et al (1997) Phase II study of trimetrexate, fluorouracil and leucovorin for advanced colorectal cancer. J Clin Oncol 15:915–920PubMedGoogle Scholar
  55. 55.
    Kreuser ED, Szelenyi H, Hohenberger P et al (1997) Trimetrexate, 5-fluorouracil and folinic acid: an effective regimen in previously untreated patients with advanced colorectal carcinoma (abstract). Proc Am Soc Clin Oncol 16:294AGoogle Scholar
  56. 56.
    Rougier P, Buyse M, Ryan L et al (1997) Meta-analysis of all trials comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients with advanced colorectal cancer (abstract). Proc Am Soc Clin Oncol 16: 267AGoogle Scholar
  57. 57.
    Van Cutsem E, Findlay M, Osterwalder B et al (2000) Capecitabine, an oral fluoropyrimidine with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18:1337–1345PubMedGoogle Scholar
  58. 58.
    Hoff P, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292PubMedGoogle Scholar
  59. 59.
    Pazdur R, Douillard J, Skillings JR et al (1999) Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 18:1009AGoogle Scholar
  60. 60.
    Rougier P, Bugat R, Douillard JY et al (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251–260PubMedGoogle Scholar
  61. 61.
    Pitot HC, Wender DB, O’Connell MJ et al (1997) Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910–2919PubMedGoogle Scholar
  62. 62.
    Cunningham D, Pyrhonen S, James R et al (1998) Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418PubMedCrossRefGoogle Scholar
  63. 63.
    Rougier P, Van Cutsem E, Bajetta E et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407–1412PubMedCrossRefGoogle Scholar
  64. 64.
    Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905–914PubMedCrossRefGoogle Scholar
  65. 65.
    Douillard J, Cunningham D, Roth A et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041–1047PubMedCrossRefGoogle Scholar
  66. 66.
    Sargent DJ, Niedzwiecki D, O’Connell MJ, Schilsky RL (2001) Recommendations for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144–145PubMedCrossRefGoogle Scholar
  67. 67.
    Machover D, Diaz-Rubio E, deGramont A et al (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95–98PubMedCrossRefGoogle Scholar
  68. 68.
    Becouarn Y, Yehou M, Ducreux M et al (1998) Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer. J Clin Oncol 16:2739–2744PubMedGoogle Scholar
  69. 69.
    De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMedGoogle Scholar
  70. 70.
    Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Raynor A, Ignoffo RJ et al (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7:1646–1654PubMedGoogle Scholar
  71. 71.
    Kemeny N, Daly J, Reichman B et al (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patents with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107:459–465PubMedGoogle Scholar
  72. 72.
    Martin JK Jr, O’Connell MJ, Wieand HS et al (1990) Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 125:1022–1027PubMedCrossRefGoogle Scholar
  73. 73.
    Chang AE, Schneider PD, Sugarbaker PH et al (1987) A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206:685–693PubMedCrossRefGoogle Scholar
  74. 74.
    Kemeny MM, Goldberg D, Beatty JD et al (1986) Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal cancer. Cancer 57:492–498PubMedCrossRefGoogle Scholar
  75. 75.
    Rougier P, Laplanche A, Huguier M et al (1992) Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10:1112–1118PubMedGoogle Scholar
  76. 76.
    Meta-analysis Group in Cancer (1996) Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88:252–258CrossRefGoogle Scholar
  77. 77.
    Kemeny N, Huang Y, Cohen AM et al (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039–2048PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • H. L. Kindler
  • R. L. Schilsky

There are no affiliations available

Personalised recommendations